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Introduction: Vaccination is a key intervention to reduce infectious disease mortality and morbidity
amongst older individuals. Identifying social factors for vaccine uptake enables targeted interventions
to reduce health inequalities.
Objective: To systematically appraise and quantify social factors associated with vaccine uptake amongst
individuals aged 60 years from Europe.
Methods: We searched Medline and Embase from inception to 24/02/2016. The association of vaccine
uptake was examined for social factors relevant at an individual level, to provide insight into individuals’
environment and enable development of targeted interventions by healthcare providers to deliver equi-
table healthcare. Factors included: living alone, marital status, education, income, vaccination costs, area-
level deprivation, social class, urban versus rural residence, immigration status and religion. Between-
study heterogeneity for each factor was identified using I2-statistics and Q-statistics, and investigated
by stratification and meta-regression analysis. Meta-analysis was conducted, when appropriate, using
fixed- or random-effects models.
Results: From 11,754 titles, 35 eligible studies were identified (uptake of: seasonal influenza vaccine (SIV)
only (n = 27) or including pneumococcal vaccine (PV) (n = 5); herpes zoster vaccine (n = 1); pandemic
influenza vaccine (n = 1); PV only (n = 1)). Higher SIV uptake was reported for individuals not living alone
(summary odds ratios (OR) = 1.39 (95% confidence interval (CI): 1.16–1.68). Lower SIV uptake was
observed in immigrants and in more deprived areas: summary OR = 0.57 (95%CI: 0.47–0.68) and risk
ratio = 0.93 (95%CI: 0.92–0.94) respectively. Higher SIV uptake was associated with higher income
(OR = 1.26 (95%CI: 1.08–1.47)) and higher education (OR = 1.05 (95%CI: 1–1.11)) in adequately adjusted
studies. Between-study heterogeneity did not appear to result from variation in categorisation of social
factors, but for education was partly explained by varying vaccination costs (meta-regression analysis
p = <0.0001); individuals with higher education had higher vaccine uptake in countries without free vac-
cination.
Conclusions: Quantification of associations between social factors and lower vaccine uptake, and notably
living alone (an overlooked factor in vaccination programmes), should enable health professionals target
specific social groups to tackle vaccine-related inequalities.
 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Vaccination is an important intervention to prevent infections
amongst older individuals, who have increased susceptibility to
infections and often experience more severe outcomes [1–3]. A
successful vaccination programme depends not only on vaccine
effectiveness and well-organized programme delivery but also on
high vaccination uptake [3]. Inequalities in vaccine uptake
amongst older individuals could be related to social factors: the
social circumstances of living and working [4–6]. Determining
the association between social factors and vaccine uptake helps
to quantify any vaccination inequalities in specific population
groups and assists health care providers in planning targeted inter-
ventions and making any necessary changes to vaccination pro-
grammes. The social factors affecting vaccine uptake may vary
with age and with the type of vaccine [4–7]. A 2011 systematic
review summarised the association of social determinants of
health with uptake of a single vaccine (seasonal influenza (SIV))
for older individuals (aged 65 years), without quantitative syn-
thesis [6]. This previous study found conflicting associations of fac-
tors such as education, marital status, ethnicity, socio-economic
level and place of residence, without undertaking a comprehensive
assessment of between-study heterogeneity [6].
The social factors associated with SIV uptake may be different
from other vaccines used for older adults such as pneumococcal
and herpes zoster vaccines that are not administered annually.
The objective of this review was to systematically appraise and
quantify the association of social factors with uptake of vaccines
amongst individuals aged 60 years from Europe including a
detailed between-study heterogeneity assessment when neces-
sary. It was anticipated that the studies from the European region
may be more homogenous compared to those from low-income
settings, making data synthesis more feasible.
2. Methods
2.1. Search strategy
This review formed part of a larger search for studies exploring
social determinants of vaccine uptake in Europe for all age groups.
The wider search ensured that studies spanning different age
groups, including subgroups of older individuals, were not
potentially missed. The data sources comprised Medline and
Embase, searched from inception to 24/02/2016. Search terms (text
words and subject headings) were drawn up for four search con-
cepts: social factors, the European region [8], vaccination and
uptake. The search included articles, letters and conference
abstracts published in English. Additionally, reviews of vaccine
uptake (worldwide from the last five years) were searched to iden-
tify further European studies. The detailed search strategy is pro-
vided in Appendix-1. Reference lists of all eligible studies and
reviews were also searched.
To identify social factors associated with vaccine uptake, we
adapted the conceptual framework developed by the World Health
Organisation’s Commission on Social Determinants of Health
(Appendix-2) [7] for tackling health inequalities globally. This
framework provides a comprehensive approach for identifying
complex relationships between social factors and inequality, and
how to plan and implement interventions. We sought evidence
for social factors relevant at an individual level or provided insight
into individuals’ environment that could assist healthcare provi-
ders to target specific social groups for equitable healthcare deliv-
ery. The following factors were identified as possible determinants
of vaccine uptake: country of birth, religion, urban/rural residence,
marital status, living arrangements (living with others versus liv-
ing alone), and socio-economic position (education, income (indi-
vidual or household), type of health insurance, area-level socio-
economic status (SES), social class/occupation). For the purposes
of this review, we did not examine factors that were possible medi-
ators of the main factors of interest: knowledge, attitude and
beliefs, access to healthcare and health status/co-morbidities
(Appendix-2).
The titles and abstracts of the records retrieved were screened
for full text assessment based on a priori inclusion criteria (Appen-
dix 3). Studies reporting the effect of one or more social factor of
interest on vaccine uptake amongst individuals aged 60 years
from Europe [8] were potentially eligible. The outcome was any
routine vaccination programme and/or one-off vaccination such
as pandemic mass vaccinations or catch-up vaccinations; travel
or occupational health vaccinations were excluded. Eligible study
designs comprised cross-sectional, ecological, case-control or
cohort studies. We further restricted to studies that quantified
the relationship between social factors of interest with vaccine
uptake by either reporting relative risks or providing raw data
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for their calculation; studies presenting the results of hypothesis
testing without reporting effect measures were described narra-
tively. Multiple papers describing the same study population were
included once. The abstracts of the records that appeared to meet
these screening criteria were selected for a full text review.
The eligibility criteria were applied by one reviewer (AJ) to the
titles/abstracts identified, for full-text assessment. A random sam-
ple (10%) of titles considered ineligible were screened indepen-
dently by two other reviewers (ST and AJVH) (no disagreements
were observed). Of the total records identified for full text review,
the eligibility for 10% of the records for which eligibility was ini-
tially unclear was resolved by discussion (ST, AJ and AJVH).
2.2. Data extraction
Data were extracted by one reviewer (AJ). Information was
extracted for: author, study characteristics (year, country, design,
size, participants) vaccine types, social factors, effect estimates
and confounders used for adjusted effect estimates.
2.3. Quality assessment
Quality assessment was performed by one reviewer (AJ) includ-
ing detailed discussions with the second reviewer (ST), using the
Cochrane approach for risk of bias adapted for observational data
[9,10]. Risk of bias (categorised as low, high or unclear risk) was
assessed for the following five domains: selection bias, missing
data, misclassification of vaccination status, misclassification of
social factors (including consideration of timeliness for time-
varying social factors - marital status, living alone, rural/urban res-
idence, area-level SES, income and insurance status), and con-
founding bias. Details of the bias assessment are provided in the
Appendix-4.
2.4. Data analysis
Forest plots of effect estimates (odds ratios (OR) or risk/rate
ratios (RR)) were generated for each social factor, stratified by vac-
cine type. Raw data were used to calculate ORs if effect estimates
were unavailable. The effect estimates from the most appropriate
model (ideally, controlling for confounding and not adjusted for
mediating variables) were used when available, otherwise the
unadjusted estimate was used. For social factors with more than
two categories, reported estimates for the highest or lowest cate-
gory were selected. To address varying choice of baseline exposure
group in different studies, effect estimates for a comparable base-
line were re-calculated when possible using raw data; if the expo-
sure variable was binary, the effect estimates were reversed for
studies that used a different baseline. Similarly, effect estimates
for non-uptake of vaccination were reversed to obtain estimates
for vaccine uptake. Studies were described narratively if such com-
parisons were impossible or if estimates from probit or linear prob-
ability models were presented.
Between-study heterogeneity was explored using I2-statistics
and the Cochrane Q-statistic [11]. When the I2-statistic was
50% fixed effects meta-analyses [11] were conducted. When
between-study heterogeneity (I2 > 50%) was identified for a partic-
ular factor, a random effects meta-analysis was conducted if effect
estimates were all broadly in the same direction, but was not
attempted when effect estimates were in opposing directions as
the summary estimate was considered uninformative [11].
Between-study heterogeneity was explored as follows: stratify-
ing by vaccine type (influenza vs other vaccine uptake), different
effect measures (OR or RR), re-categorising exposures with >2 cat-
egories (when feasible) to maximise homogeneity of exposure def-
initions; restricting analyses to studies reporting adequately
adjusted estimates (Appendix 4), and stratifying results by
whether the vaccine was available free-of-charge in the country
(to see whether costs of vaccination modified effect estimates).
Meta-regression analysis was conducted to further investigate
heterogeneity for social factors with at least 10 studies, assessing:
vaccine type (influenza vs other vaccine uptake); OR/RR as effect
estimates; heterogeneity in the categories chosen for the social fac-
tor; confounding bias; whether the vaccine was available free-of-
charge; and any over-adjustment of effect estimates (inclusion of
hypothesized mediating variables in multivariable models).
Data were analysed using Stata 14 software package (StataCorp
LP, College Station, TX, USA).
3. Results
A total of 11,754 titles were identified, of which 479 titles
(including one title identified from references) were evaluated
for full text review (Appendix-5) resulting in 35 eligible studies
conducted between 1997 and 2015 (Appendix-6). Most were
cross-sectional with five cohort studies and one case-control study.
Three studies reported data for more than one European country
[12–14], with the remaining 32 studies conducted in 11 countries
(Table 1), Spain being the most frequent (n = 11) followed by the
UK (n = 5). The studies ascertained uptake of SIV (n = 27), pneumo-
coccal vaccine (PV) (n = 1), both SIV and PV (n = 5), SIV and pan-
demic influenza vaccine (n = 1), and SIV and herpes zoster
vaccine (n = 1).
Amongst studies providing effect estimates education was the
most frequent social factor investigated (n = 14), followed by living
alone (n = 13), and country of birth (n = 11). The least studied fac-
tors were health insurance (n = 3) and religion (n = 1) (Table 1).
Two studies reported effect estimates for some social factors but
only statistical evidence (without effect estimates) for country of
birth [15] and for private medical insurance [16] (Appendix-7).
Nine additional studies [17–25] (Appendix-7) that did not provide
effect estimates were summarised narratively.
3.1. Quality assessment
As shown in Table 2 and Appendix-8, studies had low risk of
bias for outcome and exposure measurement but confounding bias
was common. The confounding bias mostly resulted from lack of
adjustment for at least one other social factor (Appendix-4) in mul-
tivariable models.
3.2. Social factors of vaccine uptake
3.2.1. Living alone
Of the nine studies considered for meta-analysis, six classified
living alone as a binary variable, and for the other three [26–28]
studies ‘‘living as a couple” was compared to living alone. Although
results were heterogeneous, studies consistently showed increased
uptake amongst those not living alone, with an overall 25% and
53% increase for SIV uptake after restricting analysis to adequately
adjusted studies and stratifying by vaccine cost respectively
(Fig. 1). Re-analysis of living arrangements as a binary variable
(Fig. 1) did not reduce heterogeneity.
Two studies [29,30] categorised living arrangements differently.
One (comparing smaller versus larger households) reported
increased uptake amongst individuals from large households
[29], whereas the other (living with children versus not living with
children) [30] reported lower vaccine uptake amongst those living
with children. The studies that used probit or linear regression
models found negative associations between vaccine uptake and
housing density [31] and those living with children [14]. The single
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Table 1
Summary of studies reporting associations of social determinants with vaccine uptake (N = 35).
First author Country Study period Sample size Study population Vaccine Social determinants and their association with vaccine uptake
SES (A)a Incob SCc COBd Edue LAf RSg Relih Resi HIj
Cross-sectional studies
1 Abramson
[32]
Israel 1997 626 People aged 65 years with a telephone and registered at the
Jerusalem community centre
SIV N*d N* ;* N*
2 Aguilar [56] Spain 2010–2011 104,427 Computerised vaccination records for all non-institutionalised
individuals 65 years covered by Navarre Health Service
SIV ;* N*
3 Barrett & Mc
Hugh [33,47]
RoI October 2009–
February 2011
3,510 Community residents aged 65 years from The Irish
Longitudinal Study on Ageing (TILDA)
SIV ; ; "
4 Bodekar [15] Germany March–June 2014 825 Respondents (aged 60 years) to a nationwide telephone survey SIV N
5 Bohmer [37] Germany July 2008–June
2009
8,458 Respondents (aged 60 years) to a national telephone health
survey
SIV N* N
6 Burns [57] UK 2001–2002 444 Adults aged 65 years interviewed at public places around
Birmingham
SIV ;* "*
7 Carreno-
Ibanez [58]
Spain March–June 2014 76,782 Individual records from the primary care electronic records for
people aged 60 years with chronic bronchitis or emphysema
from the Autonomous Community of Madrid
PV ;
8 Chiatti
[26,48,59]
Italy December 2004–
September 2005
25,183 (3,738
with COPD)
People (aged 65 years) from the ‘‘Healthstatus of the
population and use of health services in Italy” survey (ISTAT 8)
and a secondary analysis of individuals who self-reported a
diagnosis of COPD
SIV N* "* N* N* ;*
9 Christenson
[34]
Sweden December 2000–
May 2001
7,631 Responders (aged 65 years) of a postal survey sent to people
registered with the Stockholm County Council Population
Register
SIV &
PV
" ;
10 Crawford [12] UK and RoI 2004 2,033 Community residents (aged 65 years) surveyed as a part of
‘‘Healthy Aging Research Programme”
SIV N* N* N* N*
11 Damiani [35] Italy September 1999–
June 2000
24,564 Respondents (aged 65–89 years) to the Italian national survey SIV "* N* N* ;*
12 de Souto [42] France May–July 2011 6,275 Residents from 175 nursing homes in the Midi-Pyrenees region SIV &
PV
SIV:
N*;
PV ;*
13 Jimenez-
Garcia [60]
Spain 2003 6,134 Non-institutionalised participants (aged 65 years) in the
Spanish National Health survey
SIV N*
14 Jimenez-
Garcia [61]
Spain June 2006–June
2007
7,835 Non-institutionalised respondents (aged 65 years) to the
Spanish National Health survey
SIV ;*
15 Jimenez-
Garcia [62]
Spain November 2004–
June 2005
1,629 Respondents (aged 65 years) to the ‘‘Madrid City Health
Survey: ESCM 0500
SIV N*
16 Jimenez-
Garcia [63]
Spain July 2011–June
2012
5,725 Non-institutionalised respondents (aged 60 years) to the
Spanish National Health Survey
SIV ;*
17 Jimenez-
Garcia [64]
Spain 2012–2013 1,307,165 Records of people aged 60 years registered with the public
health system of the Autonomous Community of Madrid
SIV ;*
18 Kroneman
[29]
Sweden April–May 2004 &
March–April 2005
612 Respondents (aged 65 years) to a national telephone survey SIV N*
19 Landi [13] 11
countries^
2001–2003 3,878 Participants from urban areas aged 65 years from 11 European
countries that took part in the ‘‘Aged in Home Care (ADHOC)
project” of EU
SIV "* "*
20 Mamelund
[36]
Norway November 2008 354 Non-institutionalised participants aged 65 years of a national
telephone survey
SIV N N N
21 Nexoe [65] Denmark September 1996 &
February 1997
1,204 Respondents to postal questionnaires aged 65 years identified
from the Civil Registration System
SIV "*
22 Opstelten
[45]
Netherlands 1999 666 Respondents to a postal questionnaire, aged 65 years and
registered with 4 general practices in Amersfoort town
SIV and
PV
;*
23 Opstelten
[49]
Netherlands September 2007 1,221 Respondents to postal questionnaire, aged 65 years and
registered with 3 general practices in Amersfoort town
HZ &
SIV
;*
24 Pena-Rey [50] Spain January 2000 1,111 Participants (aged 65 years) in a women’s social and health SIV "* N ;* N*
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Table 1 (continued)
First author Country Study period Sample size Study population Vaccine Social determinants and their association with vaccine uptake
SES (A)a Incob SCc COBd Edue LAf RSg Relih Resi HIj
survey in Galicia
25 Sarria-
Santamera
[16]
Spain 1997 1,148 Non-institutionalised participants (aged 65 years) in the
Spanish National Health survey (ENS)
SIV N N
26 Schmitz [14] 15
countries
2004 & 2006 8,891 Respondents aged 65 years from the first and the second wave
of the Survey of Health, Ageing and Retirement in Europe
(SHARE)
SIV "*a ;* a f "* a s
27 Shahrabani
[31]
Israel 1999–2000 4,083 Respondents (aged 60 years) to the Health Survey of the
Central Bureau of Statistics
SIV ;* a e N* a ;* a g ;* a
28 Sintes [28] Spain May 2005–January
2007
1,702 Non-institutionalised patients aged 65 years admitted with
community acquired pneumonia to 3 acute general hospitals in
Catalonia and Galicia
SIV &
PV
SIV:
N,
PV: "
SIV:
N,
PV:;
"* N
29 Wershof
Schwartz [43]
Israel 2008–2009 136,944 Individuals aged 65 years and registered with Maccabi
Healthcare Services
SIV &
PV
;* ;* "*
Casecontrol study
30 Van Essen
[46]
TN 1993–1994 181 Respondents (aged 65 years) to a postal questionnaire,
registered with seven family practices situated in a suburban
area
SIV N* N*
Cohort studies
31 Breeze [41] UK 1997–2000 29,731 People aged >74 years with available flu vaccination records
registered with general practices in the UK taking part in the
‘‘Trial of Assessment and Management of Older People in the
Community Study”
SIV N* N* N*
32 Mangtani
[27]
UK 2000 5,572 People aged >74 years from the ‘‘Trial of Assessment and
Management of Older People in the Community”
SIV N* N* " ; "*
33 Martinez-Baz
[30]
Spain 2010–2011 64,245 Individual records of non-institutionalised people aged
65 years and previously vaccinated in 2009–2010 Navarre
SIV ;* ;*h N*
34 Sammon [44] UK August 2009–June
2010
353,921 Individuals aged 65 years in clinical risk groups and registered
with a practice contributing to the General Practice Research
Database at the beginning of the H1N1 vaccination campaign
SIV &
PIV
SIV:
N*b;
PIV:;* b
35 Shah [66] UK June 2008–
January 2009
387,568 Individual records of community and care (nursing and
residential) home residents aged 65–104 years and registered
with a practice contributing to The Health Improvement
Network primary care database
SIV ;*
Total number
of studies (%)
5 (14%) 10
(29%)
5
(14%)
11
(31%)
14
(40%)
13
(37%)
9 (26% 1
(3%)
9
(26%)
3
(9%)
SES(A) – socio-economic status area a most deprived versus least deprived (reference group) except for bSammon et al. (3rd quintile: reference group).
Inco – income b Highest income level versus lowest income level (reference group).
SC – social class c Lowest social class versus highest social class (reference group).
COB – country of birth d Immigrants versus native (reference group) (dAbramson et al.: others versus those from Asia/Africa (reference group), aprobit marginal probabilities eShahrabani et al. individuals from USSR (after 1990)
versus native (reference group)).
Edu – education e Highest education level versus lowest education level (reference group).
LA – living arrangements f Not living alone versus living alone/smaller household size (reference group); fSchmitz et al. number of children in household (ordinal variable); gShahrabani et al. housing density (ordinal variable);
hMartinez-Baz et al. living with children aged <15 years versus not living with children aged <15 years (reference group).
RS – relationship status g Not married versus married (reference group); sSchmitz et al. no partner (reference group).
Reli – Religion h Not religious versus religious (reference group).
Res – Residence i Urban versus rural area (reference group).
HI – health insurance j Private insurance versus no private insurance (reference group).
SIV seasonal influenza vaccine PIV pandemic influenza vaccine PV pneumococcal vaccine HZ herpes zoster vaccine.
N – not associated with vaccine uptake. *adjusted estimates ; lower vaccine uptake " higher vaccine uptake.
RoI – Republic of Ireland, COPD – Chronic Obstructive Pulmonary Disease.
^11 countries Czech Republic, Denmark, Finland, France, Germany, Iceland, Italy, The Netherlands, Norway, Sweden, UK.
15 countries Austria, Belgium, Czech Republic , Denmark, France, Germany, Greece, Ireland, Italy, The Netherlands, Poland, Spain, Sweden, Switzerland & Israel.
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Table 2
Quality assessment of the studies included in the review.
Study 
type & 
Ref.
Social determinants and bias 
SB OM 
Area SES Income  Social class COB  Educaon Living alone Marital status Religion Residence Insurance 
Cross-
seconal EM CB MD EM CB MD EM CB MD EM CB MD EM CB MD EM CB MD EM CB MD EM CB MD EM CB MD EM CB MD 
[32] L L                   L L U L L U       L L U L L U             
[56] L L                   L L L                         U L L       
[33, 47] H L       H H H             L H L                         H H L 
[15] H L                         L H L                               
[37] H L       L L U             L H U                               
[57] L L             L L L             L L L                         
[58] L L                   L H L                                     
[26, 48, 
59] U L L L L L L L       L L L L L L L L L                   
[34] L L                         L H L       L H L                   
[12] H L             L L U             L L U L L U       L L U       
[35] U L       L L L L L L       L L L       L L L                   
[42] H L                                                 L L L       
[60] U L                   L H L                                     
[61] U L                   L H L                                     
[62] U L                   L H U                                     
[63] U L                   L H L                                     
[64] L L                   L H L                                     
[29] U L                               L H U                         
[13] U L       L L L                   L L L                         
[36] H L       L H H             L H L L H L                         
[65] H L                               L H L                         
[45] H L                                                       L H L 
[49] H L                         L H L                               
[50] L L       L L L             L H L       L L L       L L L       
[16] L L       L H L             L H L                               
[14] U L                         L L U L L U L L U                   
[31] U L                   L L U L L U L L U L L U                   
[28] U L             L H L       L H L L H L* L             L H L       
[43] L L H L L             L L L                         L L L       
Cohort 
[41] U L L L L L L L                                     L L L       
[27] L L L L L L L L                   L H L L H L       L L L       
[30] U L                   L L U       U L U             U L U       
[44] U L U H U                                                       
[66] U L U H L                                                       
Case-
control 
[46] L L                               L L L                   L L L 
Ref. – reference, SES – socioeconomic status, COB – country of birth, SB – selection bias, OM – outcome misclassification, EM – exposure misclassification, CB – confounding
bias, MD – missing data, L – low risk of bias, U – unclear risk of bias, H – high risk of bias.
Red cell with letter H signifies high risk of bias.
Green cell with letter L signifies low risk of bias.
Yellow cell with letter U signifies unclear risk.
*Low risk of bias for pneumococcal vaccine.
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Seasonal influenza
van Essen (The Netherlands)
Nexoe (Denmark)
Mangtani (UK)
Burns (UK)
Landi (multinational )
Crawford (UK and RoI)
Chiatti (Italy)
Sintes (Spain)
Mamelund (Norway)
Subtotal  (I-squared = 82.7%, p =< 0.0001)
Pneumococcal
Sintes (Spain)
Author
1993
1996-1997
2000
2001-2002
2001-2003
2004
2004-2005
2005-2007
2008
2005-2007
Study period
1.79 (0.40, 9.09)
1.59 (1.03, 2.48)
1.70 (1.51, 1.90)
2.25 (1.35, 3.73)
1.28 (1.11, 1.49)
1.14 (0.83, 1.67)
1.07 (0.98, 1.17)
1.51 (1.09, 2.13)
1.21 (0.79, 1.86)
1.39 (1.16, 1.68)
1.71 (1.20, 2.46)
*
Odds-ratio (95% CI)Living arrangement: all studies (baseline: living alone)
Chiatti (Italy)
Sintes (Spain)
Landi (multinational )
Seasonal influenza
Burns (UK)
van Essen (The Netherlands)
Crawford (UK and RoI)
Subtotal  (I-squared = 65.3%, p = 0.021)
Pneumococcal
2004-2005
2005-2007
2001-2003
2001-2002
1993
2004
1.07 (0.98, 1.17)
1.71 (1.20, 2.46)
1.28 (1.11, 1.49)
2.25 (1.35, 3.73)
1.79 (0.40, 9.09)
1.14 (0.83, 1.67)
1.25 (1.03, 1.51)*
Seasonal influenza: free
van Essen (The Netherlands)
Nexoe (Denmark)
Mangtani (UK)
Burns (UK)
Chiatti (Italy)
Sintes (Spain)
Subtotal  (I-squared = 89.1%, p =<0.0001)
Seasonal influenza: paid
Mamelund (Norway)
Pneumococcal: free
Sintes (Spain)
1993
1996-1997
2000
2001-2002
2004-2005
2005-2007
2008
2005-2007
1.79 (0.40, 9.09)
1.59 (1.03, 2.48)
1.70 (1.51, 1.90)
2.25 (1.35, 3.73)
1.07 (0.98, 1.17)
1.51 (1.09, 2.13)
1.53 (1.15, 2.04)
1.21 (0.79, 1.86)
1.71 (1.20, 2.46)
*
Seasonal influenza
van Essen (The Netherlands)
Nexoe (Denmark)
Mangtani (UK)
Burns (UK)
Landi (multinational)
Crawford (UK and RoI)
Chiatti (Italy)
Sintes (Spain)
Mamelund (Norway)
Subtotal  (I-squared = 91.4%, p =< 0.0001)
Pneumococcal
Sintes (Spain)
1993
1996-1997
2000
2001-2002
2001-2003
2004
2004-2005
2005-2007
2008
2005-2007
1.79 (0.40, 9.09)
1.59 (1.03, 2.48)
1.57 (1.41, 1.74)
2.25 (1.35, 3.73)
1.28 (1.11, 1.49)
1.14 (0.83, 1.67)
0.93 (0.88, 0.99)
1.44 (1.07, 1.93)
1.21 (0.79, 1.86)
1.10 (1.05, 1.15)
1.69 (1.26, 2.26)
Living arrangement: adjusted studies (baseline: living alone)
Living arrangement: studies cost stratified^(baseline: living alone)
Living arrangement: analyzed as binary variable (baseline: living alone)
Seasonal influenza
Abramson (Israel)
Damiani (Italy)
Mangtani (UK)
Pena-Rey (Spain)
Christenson (Sweden)
Crawford (UK and RoI)
Chiatti (Italy)
Subtotal  (I-squared = 74.0%, p = 0.001)
Pneumococcal
Christenson (Sweden)
1997
1999-2000
2000
2000
2000-2001
2004
2004-2005
2000-2001
0.47 (0.28, 0.78)
0.82 (0.74, 0.91)
0.54 (0.44, 0.67)
0.69 (0.50, 0.95)
0.76 (0.69, 0.84)
1.30 (0.80, 2.10)
0.82 (0.76, 0.89)
0.73 (0.66, 0.80)
Marital status: all studies (baseline: married)
Marital status
Seasonal influenza
Abramson (Israel)
Damiani (Italy)
Pena-Rey (Spain)
Crawford (UK and RoI)
Chiatti (Italy)
Subtotal  (I-squared = 56.1%, p = 0.06)
1997
1999-2000
2000
2004
2004-2005
0.47 (0.28, 0.78)
0.82 (0.74, 0.91)
0.69 (0.50, 0.95)
1.30 (0.80, 2.10)
0.82 (0.76, 0.89)
Marital status: adjusted studies (baseline: married)
Marital status: studies cost stratified~ (baseline: married)
Seasonal influenza: free
Abramson (Israel)
Damiani (Italy)
Mangtani (UK)
Pena-Rey (Spain)
Chiatti (Italy)
Subtotal  (I-squared = 78.4%, p = 0.001)
Seasonal influenza: paid
Christenson (Sweden)
Pneumococcal: Paid
Christenson (Sweden)
1997
1999-2000
2000
2000
2004-2005
2000-2001
2000-2001
0.47 (0.28, 0.78)
0.82 (0.74, 0.91)
0.54 (0.44, 0.67)
0.69 (0.50, 0.95)
0.82 (0.76, 0.89)
0.70 (0.60, 0.83)
0.76 (0.69, 0.84)
0.73 (0.66, 0.80)
*
*NOTE: Weights are from random effects analysis
RoI Republic of Ireland
^ 2 multinational studies excluded
~ 1 multinational study excluded
Seasonal influenza
Abramson (Israel)
Damiani (Italy)
Pena-Rey (Spain)
Mangtani (UK)
Christenson (Sweden)
Crawford (UK and RoI)
Chiatti (Italy)
Subtotal  (I-squared = 94.8%, p =< 0.0001)
Pneumococcal
Christenson (Sweden)
1997
1999-2000
2000
2000
2000-2001
2004
2004-2005
2000-2001
0.47 (0.28, 0.78)
1.02 (0.97, 1.07)
0.69 (0.50, 0.95)
0.60 (0.54, 0.67)
0.76 (0.69, 0.84)
0.61 (0.50, 0.75)
0.82 (0.76, 0.89)
0.73 (0.66, 0.80)
Not favours vaccine uptake  Favours vaccine uptake 
1.2 1.5 2.5 9.5
Marital status: analyzed as binary variable (baseline: married)
Fig. 1. Effect of living arrangements and marital status on vaccine uptake.
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UK study that did not provide effect measures, found no associa-
tion between living arrangements (categorised as a seven-level
variable) and SIV uptake amongst patients admitted to a geriatric
ward [20] (Appendix-7).
3.2.2 Marital status
Four of the seven studies considered in the meta-analysis cate-
gorised marital status as a binary variable, for the remaining three
studies single status was compared to being married. After stratifi-
cation by vaccine type, 18–53% lower vaccine uptake was observed
amongst unmarried individuals in all studies except one [12] with
notable between-study heterogeneity (I2 = 74%, Fig. 1). Reclassify-
ing marital status in three studies as a binary variable (unmarried
versus married) did not reduce the between-study heterogeneity
(Fig. 1). Heterogeneity was reduced but still appreciable after
restricting analyses to adequately adjusted SIV uptake studies.
Results were more homogeneous after stratifying by vaccine cost;
in countries in which SIV was free-of-charge, overall uptake
amongst unmarried individuals was 30% lower compared to mar-
ried individuals (Fig. 1), echoing findings for living arrangements
(Fig. 1). The studies that used linear probability [14] or probit mod-
els [31] also found higher SIV uptake amongst married individuals
or those with a partner, as did one of the three Spanish studies that
did not provide effect measures (uptake 47.8% vs 53%) [21]; the
other two Spanish studies found no evidence for an association
between marital status and SIV uptake [16,18] (Appendix-7).
3.2.3. Education
Twelve studies were considered for meta-analysis (Fig. 2). There
was no consistent effect of higher education on vaccine uptake
after stratification by vaccine-type (I2 > 80%). Results were little
changed after re-categorising education in seven studies as a bin-
ary variable (education up to ages 12–15 years and >15 years)
[16,26,32–36] (Fig. 2). Restricting analysis to adequately adjusted
studies resulted in a consistent direction of effect (Fig. 2) with a
summary estimate of 5% higher uptake amongst those with the
highest education level.
Interestingly, stratification by vaccination cost [32,34,35,37–40]
showed marked differences. In countries where the vaccine was
provided free-of-charge there was no overall effect of education.
In contrast, in countries where a payment for vaccination was nec-
essary, higher education was associated with an overall 67%
increased odds of SIV uptake. (Fig. 2). A reverse effect (20%
decreased odds of uptake) was seen in the single Irish study, where
vaccine administration payments are means tested [39,40].
Two studies excluded from meta-analysis reported marginal
probabilities: one found no evidence of an association of education
level with SIV uptake [31] and the other (including fifteen coun-
tries) found low education level associated with lower SIV vaccina-
tion (linear probability model coefficient = 0.034) [14]. Four
further studies did not provide effect estimates: a Greek study
[24] showed higher uptake amongst those with at least primary
education whilst three Spanish studies [18,21,22] reported no evi-
dence of effect of education on SIV uptake (Appendix-7).
3.2.4. Household/individual income
The eight studies that reported ORs for income and SIV uptake
showed no consistent effect (Fig. 2). Amongst the two studies
[27,41] reporting RRs, there was no overall effect of income on
SIV uptake (Fig. 2).
Despite remaining heterogeneity, results were more consistent
after restricting to studies with adequate adjustment for confound-
ing, with an overall 26% increased odds of SIV uptake amongst
those with higher income, consistent with that observed for the
effect of education (Fig. 2). Unlike the findings for education, in
stratified analyses an overall 14% higher odds of SIV uptake
amongst those with higher income was observed in countries
offering free-of-charge vaccination [37,40] (Fig. 2). However, in a
single Irish study [33] where vaccination payment was means
tested [40], the effect of higher incomewas similar to that of higher
education: those with higher income had lower odds of SIV uptake
(Fig. 2). It was not possible to re-classify income status as a binary
variable for comparison across studies, and the exploration of
heterogeneity for this aspect was therefore not undertaken.
Four studies did not provide effect estimates for the association
of income with vaccine uptake (Appendix-7). A second Irish study
found uptake of both SIV and PV to be higher (p < 0.001) amongst
individuals entitled to free vaccine (possessors of a medical card)
compared to those who paid for vaccination [17]. Higher SIV cov-
erage was reported for individuals with lower income in urban
areas of Turkey where the vaccination was not available free-of-
charge [19]. In contrast, two Spanish studies found no evidence
of an association between income and SIV uptake [18,21].
3.2.5. Urban or rural area of residence
Eight of the nine studies (SIV n = 6, SIV and PV n = 3) with effect
estimates reported the association of vaccine uptake with the loca-
tion of individuals’ own homes (urban or rural), whilst one French
study [42] investigated the location of individuals’ nursing homes
(Fig. 3). No consistent direction of effect was observed for studies
reporting ORs for the association of SIV uptake with residence.
However, the studies that presented RRs for SIV uptake and ORs
for PV uptake found an overall 11% and 15% increase in uptake
respectively amongst urban residents (Fig. 3).
The location of nursing homes had no effect on SIV uptake, but
(in contrast to individuals living independently) a lower uptake of
PV was observed in residents in urban versus rural nursing homes
(Fig. 3).
Between-study heterogeneity for SIV uptake could not be
explained by restricting the analysis to adjusted ORs (Fig. 3) and
all studies except one [12] offered free vaccination. Again, it was
not feasible to re-categorise this exposure as binary variable.
A UK study that did not provide effect measures found no asso-
ciation between location of general practices and SIV uptake [23].
3.2.6. Area-level SES
Five UK studies reported the association of area-level SES with
vaccine uptake (SIV alone n = 3, SIV and pandemic influenza
n = 1, SIV and PV n = 1, Fig. 3). All but one study reported RRs
[43]. The reference group for one study [44] was the third quintile
of deprivation in contrast to the other four studies (the baseline
group being the least deprived area).
The results were similar to the effect of household income
(Fig. 2), with risk of SIV uptake modestly (7–11%) lower amongst
those living in most deprived areas. This effect was seen consis-
tently irrespective of vaccine type or measure of effect (Fig. 3) or
using a different baseline group. All studies were from countries
providing free-of-charge vaccination and it was not feasible to
re-categorise this exposure.
3.2.7. Private medical insurance
Two [45,46] of the three studies considered in meta-analysis
categorised insurance as a binary variable; one study [47] used a
four-level variable (Appendix-6). The latter study compared indi-
viduals with private medical insurance to those without insurance
as baseline. After stratification by vaccine types (Fig. 3), overall SIV
uptake was 67%more likely amongst individuals with private med-
ical insurance, but uptake of both SIV and PV was 62% lower
(Fig. 3). One study [46] provided adequately adjusted estimates;
all but one study [47] were conducted in countries that provided
vaccine free-of-charge (Fig. 3). SIV uptake was 72% higher amongst
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Fig. 2. Effect of education and income on vaccine uptake.
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Fig. 3. Effect of residence, area level socio-economic status and medical insurance on vaccine uptake.
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Social class
~Cost stratified studies not presented as all study 
countries offered free-of-charge vaccine
RoI Republic of Ireland *Weights are from random 
effects analysis
^ one multinational study excluded
Seasonal influenza
Jimenez-Garcia (Spain)
Jimenez-Garcia (Spain)
Jimenez-Garcia (Spain)
Wershof (Israel)
Aguilar (Spain)
Martinez-Baz (Spain)
Jimenez-Garcia (Spain)
Jimenez-Garcia (Spain)
Subtotal  (I-squared = 97.6%, p =<0.0001)
Pneumococcal
Wershof (Israel)
Carreno-Ibanez (Spain)
Subtotal  (I-squared = 96.7%, p =<0.0001)
2003
2004-2005
2006-2007
2008-2009
2010-2011
2010-2011
2011-2012
2012-2013
2008-2009
2010
0.85 (0.35, 2.06)
0.96 (0.43, 2.04)
0.34 (0.19, 0.59)
0.82 (0.80, 0.84)
0.40 (0.36, 0.45)
0.55 (0.45, 0.67)
0.60 (0.32, 0.99)
0.60 (0.57, 0.62)
0.58 (0.46, 0.73)
0.88 (0.86, 0.90)
0.60 (0.52, 0.68)
0.73 (0.50, 1.06)
*
*
Country of birth analyzed as binary variable (baseline: native)
Seasonal influenza
Wershof (Israel)
Aguilar (Spain)
Martinez-Baz (Spain)
Subtotal  (I-squared = 98.1%, p =<0.0001)
Pneumococcal
Wershof (Israel)
2008-2009
2010-2011
2010-2011
2008-2009
0.74 (0.71, 0.77)
0.40 (0.36, 0.45)
0.55 (0.45, 0.67)
0.55 (0.35, 0.85)
0.73 (0.70, 0.77)
*
Country of birth: adjusted studies (baseline: native)
Seasonal influenza
Jimenez-Garcia (Spain)
Jimenez-Garcia (Spain)
Jimenez-Garcia (Spain)
Wershof (Israel)
Aguilar (Spain)
Martinez-Baz (Spain)
Jimenez-Garcia (Spain)
Jimenez-Garcia (Spain)
Subtotal  (I-squared = 94.8%, p =<0.0001)
Pneumococcal
Wershof (Israel)
Carreno-Ibanez (Spain)
Subtotal  (I-squared = 86.3%, p = 0.007)
Author
2003
2004-2005
2006-2007
2008-2009
2010-2011
2010-2011
2011-2012
2012-2013
2008-2009
2010
Study period
0.85 (0.35, 2.06)
0.96 (0.43, 2.04)
0.34 (0.19, 0.59)
0.74 (0.71, 0.77)
0.40 (0.36, 0.45)
0.55 (0.45, 0.67)
0.60 (0.32, 0.99)
0.60 (0.57, 0.62)
0.57 (0.47, 0.68)
0.73 (0.70, 0.77)
0.60 (0.52, 0.68)
0.67 (0.55, 0.81)
Odds-ratio (95% CI)
*
*
Country of birth: all studies (baseline: native)~
Seasonal influenza
Damiani (Italy)
Burns (UK)
Crawford (UK and RoI)
Chiatti (Italy)
Sintes (Spain)
Pneumococcal
Sintes (Spain)
1999-2000
2001-2002
2004
2004-2005
2005-2007
2005-2007
0.94 (0.81, 1.08)
0.68 (0.51, 0.92)
0.95 (0.70, 1.20)
1.21 (1.11, 1.33)
1.01 (0.77, 1.35)
1.40 (1.07, 1.84)
Social class: all studies (baseline: highest class )
Subtotal  (I-squared = 80.2%, p =<0.0001)
Seasonal influenza
Damiani (Italy)
Burns (UK)
Crawford (UK and RoI)
Chiatti (Italy)
1999-2000
2001-2002
2004
2004-2005
0.94 (0.81, 1.08)
0.68 (0.51, 0.92)
0.95 (0.70, 1.20)
1.21 (1.11, 1.33)
Social class adjusted studies (baseline: highest class)
Subtotal  (I-squared = 85%, p =<0.0001)
Seasonal influenza
Damiani (Italy)
Burns (UK)
Chiatti (Italy)
Sintes (Spain)
Pneumococcal
Sintes (Spain)
1999-2000
2001-2002
2004-2005
2005-2007
2005-2007
0.94 (0.81, 1.08)
0.68 (0.51, 0.92)
1.21 (1.11, 1.33)
1.01 (0.77, 1.35)
1.40 (1.07, 1.84)
Not favours vaccine uptake  Favours vaccine uptake 
1.15 .5 2.5
Social class cost stratified studies (baseline: highest class)^
Subtotal  (I-squared = 84.5%, p =<0.0001)
Fig. 4. Effect of country of birth and social class on vaccine uptake.
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those with private medical insurance was observed in the Irish
study [47] where vaccination charges were means tested [40].
A Spanish study [16] that did not provide effect measures
reported no evidence of association of private medical insurance
with SIV uptake (Appendix-7).
3.2.8. Country of birth
Nine studies, all except one conducted in Spain, were consid-
ered for meta-analysis (Fig. 4). Overall, there was lower uptake of
vaccination amongst immigrants irrespective of vaccine type, with
uptake 43% and 33% lower for SIV and PV vaccines respectively
(Fig. 4). The summary effect estimate was near-identical after
restricting SIV studies to those with adequate adjustment of con-
founding, and after reclassifying country of birth in one study
[43] as a binary variable (Fig. 4). Stratification based on vaccine
costs was not required as all included countries offered free
vaccinations.
Two studies from Israel with effect estimates were excluded
frommeta-analysis, one [32] used a different definition for country
of birth (those born in Asia or Africa versus elsewhere) and the sec-
ond used marginal probabilities to investigate immigration status;
neither found an association with SIV uptake [31]. Two further
studies did not provide effect estimates: an Israeli study [25] found
statistical evidence for lower uptake of both SIV and PV amongst
Russian speakers compared to Arabic speakers, whilst a German
study found no evidence for lower SIV uptake amongst immigrants
[15].
3.2.9. Social class/occupation
Five studies (SIV: n = 4, SIV and PV: n = 1) provided effect esti-
mates for the association of social class with vaccine uptake
(Fig. 4). There was no consistent effect seen for SIV uptake
(I2 = 80.2%), but the single study of PV uptake (from Spain)
reported higher uptake amongst individuals from the lowest social
class [28].
Between-study heterogeneity could not be explained after
restricting to studies with adequate adjustment for confounding
or stratifying by vaccine costs (Fig. 4), and this exposure could
not be consistently re-categorised as a binary variable across stud-
ies to further explore between-study heterogeneity.
3.2.10. Religion
The one study that provided effect estimates [32], found no
strong evidence for an association with SIV uptake (religious ver-
sus not religious: OR = 1.71 (95%CI:0.96–3.03)) Another study (no
effect estimates provided) [25] reported an association of SIV
uptake with place of residence that varied with individuals’ reli-
gion: amongst Jewish individuals higher uptake was noted in rural
areas compared to urban areas (p < 0.04) whilst the association
was reversed amongst Muslim individuals(with higher uptake in
urban (80%) compared to rural areas (76%) (Appendix-7).
3.3. Meta-regression
There were sufficient studies (n = 12) to further examine the
reasons for heterogeneity for the association of education with
SIV uptake [15,16,28,32–37,48–50].
Multivariable meta-regression analyses included vaccination
cost (free versus paid), confounding bias (low or high risk of bias)
and ‘over-adjustment’ (studies that included in multivariable anal-
yses variables hypothesized to be on the causal pathway between
education and vaccine uptake). There was strong evidence
(p < 0.0001) that the association of education with vaccine uptake
varied with vaccination costs: in studies from countries (Sweden
and Norway) where the population had to pay for vaccination,
the ORs were 1.93 times the ORs reported from countries where
vaccines were available free-of-charge for some (e.g. Ireland) or
all (e.g. Spain) of the population. There was some evidence
(p = 0.05) that between-study heterogeneity could be explained
by risk of confounding bias, but little evidence that it was
explained by ‘over-adjustment’ (p = 0.2). All education studies
reported ORs and investigated SIV vaccine uptake, and thus the
type of effect estimate and vaccines were not examined.
Each study categorised education differently making it infeasible
to examine this the meta-regression model. Analyses were
repeated after excluding the study reporting both SIV and zoster
uptake (n = 11), revealing similar results, but the effect
‘over-adjustment’ could not be investigated in the reduced model
due to collinearity.
4. Discussion
To our knowledge, this is first review to quantify systematically
the effect of a wide range of social factors on vaccine uptake
amongst older individuals in Europe. Not living alone, an important
social factor for this population group, was associated with higher
SIV (39%) and PV (71%) uptake. Marital status, which is likely to be
highly correlated with living alone, also showed lower uptake of
both SIV and PV amongst unmarried individuals in all except one
study. Other characteristics associated with lower vaccine uptake
included being an immigrant (43% and 33% lower uptake for SIV
and PV respectively), and lower area-level deprivation (7% lower
uptake for SIV), highlighting that vaccination inequalities continue
to exist despite availability of free vaccines. The direction of effect
for all these factors remained even after restricting the analyses to
studies with low risk of confounding bias.
No consistent direction of effect was observed for education.
However, restricting analyses to adequately adjusted studies
showed a small (5%) overall increase of SIV uptake with higher
education. The effect of income also initially appeared heteroge-
neous, but amongst adequately adjusted studies that measured
ORs (and excluding the single study in which vaccines were not
universally supplied free-of-charge), the effect of higher income
was consistent with that of higher education. These findings con-
cur with those from a study of individuals aged 50 years from
13 European countries, which reported lower utilisation of a range
of preventative services, including SIV uptake, amongst those with
lower income and education [51]. In contrast, there was no evi-
dence of an effect of income for the two studies measuring RRs.
This could in part be explained by ORs having more extreme values
than RRs when the outcome is common [52]. Stratification by vac-
cine costs revealed contrasting results for education and income:
unlike education, income-related inequalities persisted, with
higher uptake amongst those with higher income in countries
offering free-of-charge vaccination. Contrarily in Ireland (where
vaccination payment are means-tested) [40], both lower income
and lower education were associated with higher uptake.
Overall there was no consistent effect of social class on vaccine
uptake; between-study heterogeneity could have resulted from
differences in the definition used for this exposure, although data
were not available to explore this further. The role of urban resi-
dence with vaccine uptake was also variable; although summary
estimates for two SIV studies (measuring RRs) and for two PV stud-
ies (measuring ORs) indicated higher uptake in urban areas, most
of the SIV studies showed inconsistent direction of effects for
urban residence.
Some important determinants such as religion and access to pri-
vate medical insurance were not consistently included across stud-
ies from different countries. Given increasingly diverse populations
and differences in provision of healthcare across Europe, these
determinants could be important end-points for future studies.
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Living alone was identified as an important factor associated
with lower vaccine uptake in this review and may be an indicator
for social isolation [53]. Living alone has emerged as an important
determinant of health in older populations. For example, in a 2010
systematic review, lack of social relationships was associated with
a 50% increase in mortality, comparable to the increased risk
resulting from smoking or obesity [54]. Similarly, a 2015 meta-
analysis [53] found that living alone was associated with 32%
higher mortality (OR 1.32, 95%CI 1.14–1.53). In 2013, approxi-
mately 13% of households in the European Union comprised indi-
viduals aged 65 years living alone [55]. With an increasingly
ageing population, the numbers living alone are likely to rise,
increasing the importance of preventative measures such as vacci-
nations. Interestingly in our review, living with children or increas-
ing housing density in some studies was associated with lower SIV
uptake, suggesting that not living alone also may have different
effects on vaccine uptake depending upon household composition.
Our analysis is an important update (with nineteen additional
studies) of the previous 2011 systematic review by Nagata et al.,
which assessed only SIV uptake amongst older individuals [6].
Our review extends the scope to all vaccines given routinely to
older individuals, has provided the results of quantitative synthe-
ses, and has carried out extensive investigation of between-study
heterogeneity. Our review also included religion as a social factor,
incorporates studies prior to 2011 that were not presented in this
earlier review [6], and provides more detailed analyses of social
factors such as country of birth, individual components of socio-
economic position, marital status and living alone.
Our review has several strengths. A comprehensive search strat-
egy was utilised to identify pertinent social determinants of SIV
and other vaccine uptake amongst older populations. Stringent cri-
teria for quality assessment were followed. Meta-analyses to
obtain summary estimates, and detailed exploration of the causes
of between-study heterogeneity using a priori stratification criteria
and meta-regression, allowed insight into the complex relation-
ships between various social determinants and vaccine uptake in
different countries.
Our review also has some limitations. A number of the studies
included in the review had high risk of confounding bias, and
restricting analyses to studies presenting adequately adjusted
effect estimates led to a reduced number of studies in these anal-
yses. Our use of stratification revealed some causes of between-
study heterogeneity. Meta-regression analysis, to further explore
the causes for heterogeneity for factors other than education was
not feasible due to insufficient numbers of studies. The multivari-
able meta-regression analyses for the effect of education indicated
that both vaccine costs and confounding bias independently
explained some of the heterogeneity in results. In this review the
effect of social isolation or loneliness on vaccine uptake was not
examined; individuals living alone may have strong social net-
works. The relationship between social isolation and vaccine
uptake can perhaps be explored in future research. In addition,
we hypothesized correlations between some social factors based
on our conceptual framework, but it is possible that other complex
inter-relationships between these factors may exist. Finally, we
included only studies published in English language, which could
have excluded some relevant data.
5. Conclusion
This is the first systematic review that quantifies the association
of living alone, an important social factor for older individuals,
with lower vaccine uptake. This, along with quantification of other
factors such as immigration status, deprivation and education
level, will help to target older individuals for interventions to mit-
igate vaccination inequalities. This review has also highlighted the
limitations of existing studies in terms of study quality and
between-study heterogeneity. As the role of social factors becomes
increasingly recognised for equitable healthcare delivery, the find-
ings of this review should provide guidance to healthcare providers
for addressing vaccination inequality amongst older individuals.
Our review should also help researchers to design future studies
of higher quality with potentially more standardised definitions
of social factors.
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